Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts for Orencia were accepted for presentation at the 2014 annual meeting of the American College of Rheumatology (ACR) taking place from November 14-19, 2014 in Boston, MA. This year’s data reinforce the Company’s commitment to evaluating the use of Orencia in early moderate to severe RA and the potential impact on the course of the disease.
Help employers find you! Check out all the jobs and post your resume.
